AMT Medical, a clinical-stage medtech innovator, announced a $25 million Series B financing round led by Bender Analytical Holding B.V. (BAH). New investors Invest-NL and the European Innovation Council (EIC) joined existing backers Oost NL and several angels in the round.
The funding accelerates the development of AMT’s ELANA Heart Bypass System, a minimally invasive solution designed to replace traditional open-heart bypass surgery. It will lead to robot-assisted keyhole surgery compatible with surgical robots from industry leaders.
This new funding will enable the company to pursue key initiatives, including CE marking and initial clinical trials in the US in open and robotic settings.
The ELANA Heart Bypass System enables surgeons to perform the most state-of-the-art coronary artery bypass grafting (CABG) with arterial (instead of venous) bypass grafts and through small chest incisions without stopping the heart or utilizing a heart-lung machine, which eliminates stroke risks and other complications and reduces postoperative recovery times. And this contrasts starkly with conventional methods requiring sternotomy (chest cracking), complex suturing, and long recovery times. With these improvements, the system further aims to significantly reduce the costs associated with CABG procedures.
The sutureless anastomosis technique uses a proprietary clip and an excimer laser to connect blood vessels without manual suturing. It enables precise, rapid, standardized, and reproducible graft integration while minimizing complications.
Plus, the system achieves over 50% cost reduction when used in a robotic setting. And this is driven by shorter operating room times, reduced hospital stays (patients can return home within days), fewer complications, and faster surgeon mastery compared to traditional coronary artery bypass grafting.
KEY QUOTES:
“This financing validates our mission to make open-heart bypass obsolete. By enabling same-day discharge bypass procedures, we’re not just improving outcomes – we’re redefining cardiovascular care.”
- Rutger Tulleken, CEO & Co-Founder of AMT Medical
“We are proud to support AMT as they work toward FDA clearance to bring their technology to the market in the U.S. This marks a key milestone in improving patient outcome”
- Johan Bender, CEO of Bender Analytical Holding
